Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion

Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score

(2021) Luis Pérez de Llano et al.   Journal of Allergy and Clinical Immunology-In Practice

Omalizumab response in patients with asthma by number and type of allergen

(2021) Weily Soong et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2021) Joseph K Han et al.   Lancet Respiratory Medicine

Emerging Evidence for Pleiotropism of Eosinophils

(2021) José M. Rodrigo-Muñoz et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Evolving Algorithm of Biological Selection in Severe Asthma

(2020) Nikolaos G. Papadopoulos et al.   ALLERGY

Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions

(2020) Aasha Harish et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Adherence to Inhaled Corticosteroids and Clinical Outcomes in Mepolizumab Therapy for Severe Asthma

(2020) Gráinne d'Ancona et al.   EUROPEAN RESPIRATORY JOURNAL

Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways

(2020) Didier Cataldo et al.   JOURNAL OF ASTHMA

How can we minimise the use of regular oral corticosteroids in asthma?

(2020) Arnaud Bourdin et al.   European Respiratory Review

Real-World Effectiveness and the Characteristics of a “Super-Responder” to Mepolizumab in Severe Eosinophilic Asthma

(2020) Joanne E. Kavanagh et al.   CHEST

A Critical Look at the Efficacy and Costs of Biologic Therapy for Chronic Rhinosinusitis with Nasal Polyposis

(2020) W. Colby Brown et al.   CURRENT ALLERGY AND ASTHMA REPORTS

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab

(2020) David J. Jackson et al.   DRUG SAFETY

Eosinophilic granulomatosis with polyangiitis evolution during severe eosinophilic asthma treatment with benralizumab

(2020) Alojzija Hočevar et al.   Journal of Allergy and Clinical Immunology-In Practice

Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria ‐ a systematic review for the EAACI Biologicals Guidelines

(2020) Ioana Agache et al.   ALLERGY

Blood Eosinophil Depletion with Mepolizumab, Benralizumab and Prednisolone in Eosinophilic Asthma

(2020) Angela M. Moran et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Current and Future Monoclonal Antibodies in the Treatment of Atopic Dermatitis

(2020) Peter Ip Fung Chun et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Biologics in severe asthma: The overlap endotype - Opportunities and challenges

(2020) A Bakakos et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials

(2020) Philippe Gevaert et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma

(2020) Rory Chan et al.   Journal of Allergy and Clinical Immunology-In Practice

Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis

(2020) Enrico Heffler et al.   Clinical and Translational Allergy

Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma

(2020) Joanne E. Kavanagh et al.   CHEST

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial

(2020) Florence Roufosse et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Long-term therapy response to anti-interleukin-5 biologics in severe asthma – a real-life evaluation

(2020) Katrien Eger et al.   Journal of Allergy and Clinical Immunology-In Practice

Benralizumab after sub‐optimal response to mepolizumab in severe eosinophilic asthma

(2020) Joanne E. Kavanagh et al.   ALLERGY

Oral corticosteroid sparing effects of anti-IL5/ anti-IL5 receptor treatment after 2 years of treatment

(2020) Anne Sofie Bjerrum et al.   RESPIRATORY MEDICINE

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

(2020) Tim W Harrison et al.   Lancet Respiratory Medicine

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma

(2019) Kenneth R. Chapman et al.   ALLERGY

Selection of biologics in severe asthma: a multifaceted algorithm

(2019) I Dávila et al.   JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY

Biological treatments for severe asthma: A major advance in asthma care

(2019) William W. Busse   ALLERGOLOGY INTERNATIONAL

Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis

(2019) Claus Bachert et al.   ALLERGY

Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide and their combination in severe asthma: a post-hoc analysis

(2019) Rahul Shrimanker et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: the COSMEX Study

(2019) Sandhya Khurana et al.   CLINICAL THERAPEUTICS

Management of Severe Asthma: a European Respiratory Society/American Thoracic Society Guideline

(2019) Fernando Holguin et al.   EUROPEAN RESPIRATORY JOURNAL

ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions

(2019) Arnaud Bourdin et al.   EUROPEAN RESPIRATORY JOURNAL

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

(2019) Claus Bachert et al.   LANCET

Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Allergic Asthma

(2019) Jonathan Corren et al.   Journal of Allergy and Clinical Immunology-In Practice

Biologics for the treatment of chronic rhinosinusitis with nasal polyps - state of the art

(2019) Lei Ren et al.   World Allergy Organization Journal

Characterization of severe asthma worldwide: data from the International Severe Asthma Registry (ISAR)

(2019) Wang Eileen et al.   CHEST

Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma

(2019) David J. Jackson et al.   ADVANCES IN THERAPY

Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis

(2019) Kevin Yan et al.   Immunotherapy

Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma

(2018) William W. Busse et al.   ADVANCES IN THERAPY

Eosinophilic and Noneosinophilic Asthma

(2018) Tara F. Carr et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab

(2018) Manali Mukherjee et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma

(2018) Roma Sehmi et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction

(2018) Eleanor M. Dunican et al.   JOURNAL OF CLINICAL INVESTIGATION

Eosinophils can more than kill

(2018) Claudia Berek   JOURNAL OF EXPERIMENTAL MEDICINE

VCAM-1 induces signals that stimulate ZO-1 serine phosphorylation and reduces ZO-1 localization at lung endothelial cell junctions

(2018) Hiam Abdala-Valencia et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Asthma

(2018) Alberto Papi et al.   LANCET

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

(2018) Klaus F. Rabe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

(2018) Mario Castro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Towards precision medicine in severe asthma: Treatment algorithms based on treatable traits

(2018) Andriana I. Papaioannou et al.   RESPIRATORY MEDICINE

Airway Inflammation and Inflammatory Biomarkers

(2018) Hui Lim et al.   SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies

(2018) J Mark FitzGerald et al.   Lancet Respiratory Medicine

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study

(2018) Thomas B. Casale et al.   Journal of Allergy and Clinical Immunology-In Practice

Baseline Patient Factor Impact on the Clinical Efficacy of Benralizumab for Severe Asthma

(2018) Eugene R. Bleecker et al.   EUROPEAN RESPIRATORY JOURNAL

Omalizumab for Severe Asthma: Beyond Allergic Asthma

(2018) C. C. Loureiro et al.   Biomed Research International

Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis

(2018) Karin Jonstam et al.   ALLERGY

Eosinophils Target Therapy for Severe Asthma: Critical Points

(2018) L. Brussino et al.   Biomed Research International

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

(2018) William W Busse et al.   Lancet Respiratory Medicine

Care pathways for the selection of a biologic in severe asthma

(2017) Jean Bousquet et al.   EUROPEAN RESPIRATORY JOURNAL

Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study

(2017) Christian Domingo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience

(2017) Bradley E. Chipps et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

(2017) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Severe and Difficult-to-Treat Asthma in Adults

(2017) Elliot Israel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population

(2017) Marjan Kerkhof et al.   THORAX

Emergence of Biomolecular Pathways to Define Novel Asthma Phenotypes. Type-2 Immunity and Beyond

(2016) Sally E. Wenzel   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma

(2016) Jonathan Corren et al.   CHEST

Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels

(2016) Leif Bjermer et al.   CHEST

Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma – an update

(2016) Garry M. Walsh   Expert Review of Clinical Immunology

Current concepts of severe asthma

(2016) Anuradha Ray et al.   JOURNAL OF CLINICAL INVESTIGATION

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

(2016) Eugene R Bleecker et al.   LANCET

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

(2016) Sally Wenzel et al.   LANCET

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

Reductions in eosinophil biomarkers by benralizumab in patients with asthma

(2016) Tuyet-Hang Pham et al.   RESPIRATORY MEDICINE

Value of peripheral blood eosinophil markers to predict severity of asthma

(2016) Julian Casciano et al.   BMC Pulmonary Medicine

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

(2016) Hector G Ortega et al.   Lancet Respiratory Medicine

Eosinophilic bioactivities in severe asthma

(2016) Tara F. Carr et al.   World Allergy Organization Journal

Nasal and pharyngeal eosinophil peroxidase levels in adults with poorly controlled asthma correlate with sputum eosinophilia

(2015) M. A. Rank et al.   ALLERGY

Normativa sobre asma grave no controlada

(2015) Carolina Cisneros Serrano et al.   ARCHIVOS DE BRONCONEUMOLOGIA

Asthma phenotypes and IgE responses

(2015) Antoine Froidure et al.   EUROPEAN RESPIRATORY JOURNAL

The prevalence of severe refractory asthma

(2015) Pieter-Paul W. Hekking et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Normativa sobre asma grave no controlada

(2015) Carolina Cisneros Serrano et al.   ARCHIVOS DE BRONCONEUMOLOGIA

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

(2015) Mario Castro et al.   Lancet Respiratory Medicine

Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study

(2015) David B Price et al.   Lancet Respiratory Medicine

Activation states of blood eosinophils in asthma

(2014) M. W. Johansson   CLINICAL AND EXPERIMENTAL ALLERGY

The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia

(2014) H. Ortega et al.   EUROPEAN RESPIRATORY JOURNAL

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Eosinophil Cytokines, Chemokines, and Growth Factors: Emerging Roles in Immunity

(2014) Francis Davoine et al.   Frontiers in Immunology

Exploring the Effects of Omalizumab in Allergic Asthma

(2013) Nicola A. Hanania et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Long-term Mortality Among Adults With Asthma

(2013) Zarqa Ali et al.   CHEST

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

(2013) K. F. Chung et al.   EUROPEAN RESPIRATORY JOURNAL

Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis

(2013) Bruce K. Tan et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects

(2013) William Busse et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma

(2013) Guy G Brusselle et al.   NATURE MEDICINE

Dupilumab in Persistent Asthma with Elevated Eosinophil Levels

(2013) Sally Wenzel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictors for Identifying the Efficacy of Systemic Steroids on Sustained Exhaled Nitric Oxide Elevation in Severe Asthma

(2013) Kazuto Matsunaga et al.   ALLERGOLOGY INTERNATIONAL

Global asthma prevalence in adults: findings from the cross-sectional world health survey

(2012) Teresa To et al.   BMC PUBLIC HEALTH

Severe Asthma in Adults

(2012) Mina Gaga et al.   CLINICS IN CHEST MEDICINE

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

(2012) Ian D Pavord et al.   LANCET

Asthma phenotypes: the evolution from clinical to molecular approaches

(2012) Sally E Wenzel   NATURE MEDICINE

An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FeNO) for Clinical Applications

(2011) Raed A. Dweik et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome

(2011) Jan Lötvall et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

(2010) Roland Kolbeck et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study

(2009) Tmirah Haselkorn et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma

(2009) Bob Lanier et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma

(2009) Pranabashis Haldar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia

(2009) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cluster Analysis and Clinical Asthma Phenotypes

(2008) Pranab Haldar et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE